The FDA has approved the combination of lazertinib and amivantamab-vmjw for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. This approval is contingent on the use of an FDA-approved test to detect these specific mutations. This new treatment regimen aims to offer an effective option for patients with these particular genetic alterations in their cancer.